Chronic myelogenous leukemia, BCR-ABL1 positive

This study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than …

This study looks at the long-term safety of imatinib, a daily pill for certain cancers like GIST and CML. It includes 250 patients who were already benefiting from imatinib in a previous Novartis trial and continue taking it. The main goal is to track side effects over time, with…

This phase 2 trial is testing whether adding venetoclax, a pill taken daily for 12 months, can reduce the number of leukemia stem cells that remain in the bone marrow of people with chronic myeloid leukemia (CML) who are already in deep molecular remission on standard TKI therapy…

This trial compares two oral medications for adults with chronic myeloid leukemia (CML) in its chronic phase who have already been treated with at least two other targeted therapies. Participants receive either the experimental drug asciminib or the existing drug bosutinib. The g…

This early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…

This study looked at whether people with chronic myeloid leukemia (CML) who have done very well on the drug nilotinib can safely stop taking it. 215 patients who had been on nilotinib for at least two years and had very low levels of cancer cells were enrolled. The main goal was …

This trial is testing whether a chemotherapy drug called treosulfan, given in different doses along with fludarabine, can safely prepare patients with advanced blood cancers for a stem cell transplant. The study focuses on patients who are not eligible for the standard, more inte…

This study looked at whether people with chronic myeloid leukemia (CML) who had very low levels of cancer cells could safely stop taking the drug nilotinib (Tasigna). Participants had already been treated with imatinib (Gleevec) and then nilotinib for at least 3 years. The main g…

This study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after s…

This Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…

This study tracks the safety and effectiveness of bosutinib (Bosulif) in people with chronic myelogenous leukemia (CML) who are either newly diagnosed or have not responded to or tolerated prior treatments. Researchers will monitor side effects and how well the drug controls the …

This study tests whether adjusting the daily dose of the leukemia drug dasatinib based on a patient's blood levels can improve safety and effectiveness. Adults newly diagnosed with chronic phase chronic myeloid leukemia (CML) will receive either standard dosing or a dose tailored…

This phase 2 trial tests whether adding pioglitazone (a diabetes drug) to the standard leukemia medication imatinib can eliminate remaining cancer cells in people with chronic-phase chronic myeloid leukemia (CML). Participants must have been on imatinib for at least two years and…

This trial investigates whether adjusting the dose of imatinib (Gleevec) based on the drug's level in the blood can improve outcomes for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). Participants whose imatinib blood level is low after 28 days are rand…

This study looked at the safety and effectiveness of a drug called asciminib in 85 Indian adults with a specific type of leukemia (Ph+ CML-CP). Some participants had a genetic mutation (T315I) that can make treatment harder, while others had already tried two or more other drugs.…

This study tested a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 adults with a rare, aggressive leukemia called Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia in blast phase. The goal was to see if the drugs cou…

This study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…

This study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…

This study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once…

This phase 2 trial tested whether adding asciminib to the standard drug imatinib helps people with chronic myeloid leukemia (CML) achieve deeper remission. 104 adults who had been on imatinib for at least a year without reaching very low cancer levels were randomly assigned to ad…

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's …

This study tested a new way to prepare cord blood for transplant in 30 people with high-risk leukemia or myelodysplasia. The cord blood was treated with a molecule called UM171 to help it grow more stem cells. The goal was to see if this approach is safe and helps patients recove…

This study tested the drug asciminib in 199 adults with chronic myeloid leukemia (CML) whose cancer was not well controlled after trying at least two other targeted therapies. The main goal was to see how many patients achieved a major molecular response (a key sign of disease co…

This phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…

This study tested three different starting doses (45 mg, 30 mg, and 15 mg daily) of the drug ponatinib in 283 adults with chronic phase chronic myeloid leukemia (CML) that had stopped responding to other treatments or had a specific genetic mutation (T315I). The main goal was to …

This pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…

This Phase 3 trial tested a special cord blood product called NiCord (omidubicel) against standard cord blood transplants in 125 people with blood cancers like leukemia and lymphoma. The goal was to see if NiCord helps the body rebuild its infection-fighting cells faster. Researc…

This early-stage trial tested the safety and best dose of flotetuzumab, an antibody drug, in 13 patients with advanced blood cancers that had come back or stopped responding to treatment. The drug works by blocking cancer cell growth. The main goal was to see what side effects oc…

This study tested whether the drug dasatinib can control chronic myeloid leukemia (CML) in its early chronic phase. 150 adults with newly diagnosed CML took dasatinib, and researchers measured how many achieved a major molecular response (very low levels of cancer genes) after 12…

This study tested whether a low dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (GVHD) — a common and serious complication where donor cells attack the patient's body. The trial involved 35 adults with various blood dis…

This study tested whether adding ready-made natural killer (NK) cells from a donor to a standard stem cell transplant could safely reduce the chance of cancer returning in people with high-risk myeloid cancers like acute myeloid leukemia, myelodysplastic syndrome, and chronic mye…

This study tested a stem cell transplant from half-matched (haploidentical) family donors for 34 people with various blood cancers. Patients received a reduced-intensity conditioning regimen of fludarabine, melphalan, and total body irradiation before the transplant. The goal was…

This study tested adding a drug called thiotepa to the usual chemotherapy given before a donor stem cell transplant for people with leukemia. The goal was to see if this stronger mix could help more patients stay cancer-free one year after the transplant. The study included 40 ad…

This early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…

This completed Phase 1 trial tested a new drug called IkT-001Pro in 64 healthy adults aged 18 to 55. The goal was to see if it works like the standard CML drug imatinib in the body. Participants took single doses of both drugs at different times to compare how they are absorbed a…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…

This study tested a new drug called asciminib in 56 adults with chronic myeloid leukemia (CML) whose cancer had not responded well to other treatments. The drug is taken as a pill and aims to control the disease. The main goal was to check safety and side effects over 24 weeks, w…

This study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…

This study tested whether adding a second drug (pegylated interferon) to the standard leukemia medication nilotinib helps people with newly diagnosed chronic myeloid leukemia (CML) achieve a deeper molecular response faster. About 200 adults under 65 with early-stage CML took par…

This study looked at whether people with chronic myeloid leukemia (CML) who had a good response to the drug nilotinib could switch to imatinib to maintain that response. The goal was to see if imatinib could keep the cancer under control while being easier to take and less expens…

Researchers are studying natural killer (NK) cells in people who receive stem cell transplants for leukemia. The study follows 92 patients and their donors, looking at genes called KIR and HLA that control how NK cells work. By tracking NK cells during immune recovery, researcher…

This study looks back at medical records from a single hospital in Scotland to see how well the drug bosutinib works and how safe it is for people with chronic myeloid leukemia (CML) in everyday practice. Researchers will track blood cell counts, genetic responses, and side effec…

This completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood…

This study looked back at medical records of 1,480 people with chronic-phase chronic myeloid leukemia (CML) treated in U.S. community oncology clinics between 2016 and 2022. Researchers examined which drugs were used, how doses were adjusted, and how well patients responded. The …

This study looked at how 2,298 older adults with chronic myeloid leukemia (CML) were treated in everyday medical practice, using Medicare records. Researchers tracked which drugs patients took, how often they switched treatments, and how much healthcare they used. The goal was to…

This completed Phase 1 study gave 6 healthy Chinese men a single dose of the leukemia drug TGRX-678 to see how the body absorbs, breaks down, and gets rid of it. Researchers measured radioactivity in blood, urine, and stool to map the drug's path. No treatment was given—just unde…

This study analyzed insurance claims from over 2,500 people with chronic myeloid leukemia (CML) to see how often side effects from tyrosine kinase inhibitors (TKIs) occur and how they affect treatment changes and healthcare costs. Researchers looked at side effects that required …

This study looked at how 754 people with chronic myeloid leukemia (CML) in Japan were treated with drugs called tyrosine kinase inhibitors (TKIs) between 2011 and 2019. Researchers used a hospital database to track which TKIs patients received, how often they switched or stopped …